Roche’s Vontobel Raises Price Target After Lunsumio Blood Cancer Study Success

Roche’s Swiss asset manager Vontobel raised its price target for the company’s shares to 410 Swiss francs from 405 francs following positive Phase-III trial data for its blood cancer drug Lunsumio, while maintaining a ‘Buy’ rating. The move reflects the drug’s progress in a key clinical endpoint—improvement in progression-free survival—but has not yet translated into immediate share gains. As of Thursday morning, Roche’s stock had fallen 0.8 percent in trading up to 11:25 local time, underscoring lingering market skepticism despite the study’s encouraging results.